Vyleesi Adolescent (12 to 17) Caregiver Administration Guidance

What Caregivers Need to Know Before the First Injection

Bremelanotide activates melanocortin receptors (MC1R and MC4R) in the central nervous system to increase sexual desire. The FDA approved bremelanotide in June 2019 under NDA 210557 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Adolescents aged 12 to 17 who have reached puberty and have received a confirmed HSDD diagnosis from a licensed clinician fall within the labeled population when prescribed by a qualified provider, though controlled trial data in this age cohort specifically remain limited.

Caregivers should read the full FDA-approved prescribing information before handling the autoinjector [1]. The prescribing information includes a Boxed Warning about transient increases in blood pressure and decreases in heart rate, making pre-injection baseline vital sign documentation a non-negotiable step.

Understanding the Mechanism

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It binds MC4R in the hypothalamus, a receptor pathway linked to sexual motivation in animal and human neuroimaging studies [2]. This central mechanism means the drug does not act locally at the genitals; it requires adequate time to cross the blood-brain barrier, which explains the mandatory 45-minute pre-activity window.

Confirming the Correct Indication

HSDD diagnosis in adolescents should follow the DSM-5 criteria for Female Sexual Interest/Arousal Disorder (FSIAD), which requires persistent or recurrent absence of sexual interest causing marked distress for a minimum of 6 months [3]. A caregiver should not administer bremelanotide unless a licensed clinician has documented this diagnosis and has ruled out relationship factors, medication-induced suppression (e.g., SSRIs, hormonal contraceptives), and medical conditions as primary drivers [3].

Preparing the Autoinjector

The Vyleesi autoinjector delivers a fixed 1.75 mg dose in 0.4 mL of solution. The device is single-use and pre-filled. Caregivers do not need to measure or draw up medication. This reduces dosing error substantially compared to vial-and-syringe administration [4].

Storage Requirements

Store autoinjectors at room temperature, between 68°F and 77°F (20°C to 25°C). Brief excursions between 59°F and 86°F are acceptable per USP controlled room temperature standards [1]. Do not freeze. Inspect the solution through the viewing window before each use; if the liquid appears cloudy, discolored, or contains visible particles, discard it.

Supplies to Gather

Before the injection, the caregiver should have ready:

• The Vyleesi autoinjector (confirm expiration date)
• Alcohol swabs (at least two)
• A sharps disposal container
• A blood pressure cuff (manual aneroid or validated digital device)
• Ondansetron 4 mg oral tablet or orally disintegrating tablet (ODT), if prescribed by the adolescent's provider for nausea prophylaxis [5]
• A timing device to measure the 45-minute window

The ondansetron point deserves emphasis. In the Phase 3 RECONNECT trials (Study 1: N=394; Study 2: N=398), nausea was reported in 40.4% of bremelanotide-treated participants versus 7.2% placebo, making it the most common adverse event [6]. Prophylactic antiemetic use reduced nausea severity and discontinuation rates in clinical practice experience documented in post-marketing reports reviewed in the prescribing information update [1].

Step-by-Step Injection Technique

Proper subcutaneous injection technique prevents bruising, nodule formation, and inadequate absorption. Caregivers who have not previously administered subcutaneous injections should request hands-on training from the prescribing clinician or a nurse educator before the first home dose.

Selecting and Rotating Injection Sites

Approved sites are the abdomen (at least 2 inches from the navel) and the upper outer thigh. Rotate between sites with each dose to reduce local tissue reactions. A simple rotation log (a printed body diagram marked with date and site) helps track this across multiple administrations [4].

Avoid areas with:

• Bruising, redness, or tenderness
• Tattoos or moles (makes site inspection harder post-injection)
• Scar tissue from prior injections or surgery

The Injection Sequence

1. Wash hands with soap and water for 20 seconds.
2. Clean the chosen site with an alcohol swab using a circular outward motion. Allow to air-dry for 10 seconds.
3. Remove the autoinjector cap. Do not recap once removed.
4. Pinch a fold of skin at the cleaned site using the thumb and two fingers.
5. Place the autoinjector flat against the skin at a 90-degree angle.
6. Press and hold the button firmly. A click confirms activation.
7. Maintain pressure for 5 full seconds before removing the device.
8. Release the skin fold.
9. Apply gentle pressure with a dry gauze pad. Do not rub.
10. Discard the autoinjector immediately in the sharps container.

Each step maps to FDA device instructions for use [1]. Caregivers who rush step 7 (releasing before 5 seconds) risk incomplete dose delivery.

Timing and the 45-Minute Window

Inject at approximately 45 minutes before anticipated sexual activity. The 45-minute figure reflects bremelanotide's median time to maximum plasma concentration (Tmax) of approximately 1 hour after subcutaneous injection, as reported in the pharmacokinetic data accompanying NDA 210557 [1]. Activity can begin slightly before or after the 45-minute mark, but the drug's CNS effect requires time to develop. Do not administer a second dose within 24 hours under any circumstances.

Monitoring for Adverse Effects in Adolescents

Blood Pressure and Heart Rate

The FDA placed a Boxed Warning on bremelanotide because of transient hemodynamic changes [1]. In Phase 3 RECONNECT data, the mean maximum increase in systolic blood pressure was approximately 6 mmHg and in diastolic blood pressure approximately 3 mmHg, occurring within the first 12 hours after injection [6]. Heart rate decreased by a mean of approximately 5 beats per minute during the same window.

For adolescents, who may have a more variable autonomic response than adults, caregivers should:

• Measure blood pressure and heart rate before each injection.
• Record the pre-injection baseline in a written or digital log.
• Re-check blood pressure at 60 minutes and again at 4 hours post-injection if the adolescent is sedentary or symptomatic.
• Contact the prescribing clinician if systolic BP exceeds 140 mmHg or if the adolescent reports dizziness, chest tightness, or palpitations at any point during the 12-hour post-injection window [1].

Bremelanotide is contraindicated in individuals with known cardiovascular disease, uncontrolled hypertension, or a history of significant cardiac arrhythmia [1]. These contraindications apply equally to adolescent patients.

Nausea and Vomiting Management

Nausea onset typically occurs within 1 hour of injection and resolves within approximately 2 hours in most cases [6]. If the prescriber has not already prescribed an antiemetic, caregivers should raise this with the clinician before the first dose. Oral ondansetron 4 mg is the most commonly used agent [5]. Ginger tea or ginger chews provide mild supplemental relief and carry no known interaction with bremelanotide based on current pharmacokinetic data [7].

Persistent nausea lasting more than 4 hours, or vomiting that prevents the adolescent from tolerating fluids, warrants a same-day call to the prescriber.

Focal Hyperpigmentation

Bremelanotide's activity at MC1R can cause transient focal hyperpigmentation at the injection site and, occasionally, on the face, breasts, or gums [1]. This effect is reversible after discontinuation. Caregivers should inspect the injection site 24 to 48 hours after each dose and photograph any new pigmentation changes. Documenting a baseline photograph of the abdomen and thighs before treatment begins is a practical step often recommended in dermatology literature on melanocortin-based therapies [8].

Persistent or expanding hyperpigmentation should be reported to both the prescribing clinician and a dermatologist.

Drug Interactions Relevant to Adolescents

Adolescents may take concurrent medications that interact with bremelanotide. Two interactions carry the greatest clinical weight.

Naltrexone

Bremelanotide must not be used concurrently with any naltrexone-containing product. Bremelanotide significantly reduces systemic exposure to naltrexone through an unknown mechanism identified in the NDA pharmacokinetic studies [1]. This includes buprenorphine/naloxone combinations (e.g., Suboxone), naltrexone extended-release injectable (Vivitrol), and oral naltrexone tablets used for opioid or alcohol use disorder. Caregivers managing adolescents with substance use disorder pharmacotherapy must clarify this interaction with the treating clinician.

Indomethacin

Bremelanotide reduces systemic exposure to indomethacin, a nonsteroidal anti-inflammatory drug sometimes used in adolescents for inflammatory arthritis or dysmenorrhea [1]. If the adolescent takes indomethacin regularly, the prescribing clinician should review whether bremelanotide co-administration is appropriate and whether indomethacin dosing requires adjustment [9].

SSRIs and Hormonal Contraceptives

SSRIs are common in adolescents treated for depression or anxiety and are well-documented drivers of HSDD through dopamine and serotonin pathway suppression [10]. Clinicians should evaluate whether optimizing or switching the SSRI is preferable to adding bremelanotide. If bremelanotide is prescribed despite concurrent SSRI use, no pharmacokinetic interaction has been identified in labeling, but caregivers should remain alert to additive nausea given serotonergic effects on the gut [1]. Hormonal contraceptives (combined oral contraceptives, hormonal IUDs, implants) also contribute to HSDD in some adolescents [10]. The prescribing evaluation should address whether the contraceptive method is a contributing factor.

Special Situations Caregivers May Encounter

Missed Dose

Bremelanotide is not a scheduled daily medication. A dose is simply not administered on days when sexual activity is not anticipated or desired. There is no pharmacologic consequence of not injecting on a given day. The 24-hour restriction applies only when a dose has already been administered [1].

Adolescent Refusal

An adolescent who declines injection on a specific occasion should not be pressured. HSDD treatment requires the patient's active participation and reported subjective benefit. The RECONNECT trials measured the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) as a co-primary endpoint, specifically because patient-reported desire and distress are the relevant outcomes, not caregiver-observed behavior [6]. If an adolescent consistently declines or expresses ambivalence about treatment, the caregiver should relay this to the prescribing clinician at the next visit.

Sharps Disposal

Used autoinjectors are a regulated medical waste. Place each used device immediately in an FDA-cleared sharps disposal container [11]. When the container is three-quarters full, seal it and dispose of it per local jurisdiction rules. The FDA maintains a state-by-state sharps disposal locator at FDA.gov [11]. Mail-back programs are available in many states for patients without access to local collection sites.

When to Pause or Discontinue Treatment

Caregivers should contact the prescribing clinician promptly and withhold the next dose if any of the following occur:

• Systolic blood pressure above 160 mmHg at any post-injection measurement
• New-onset facial or gum hyperpigmentation that does not resolve within 2 weeks
• Allergic reaction signs: hives, facial swelling, or difficulty breathing within 1 hour of injection [1]
• Nausea or vomiting that persists beyond 4 hours or becomes cyclical across doses
• The adolescent reports no subjective improvement in desire or distress after 8 weeks of use, which aligns with the 8-week minimum evaluation window used in RECONNECT [6]

The prescribing information notes that if the patient does not report a meaningful benefit after a trial period, treatment should be discontinued [1]. Continuing an ineffective treatment exposes the adolescent to ongoing adverse effects without therapeutic gain.

Documenting Each Administration

A written log maintained by the caregiver creates a safety record and improves clinical visits. Each entry should include:

• Date and time of injection
• Injection site used (right abdomen, left thigh, etc.)
• Pre-injection systolic/diastolic blood pressure and heart rate
• Post-injection blood pressure at 60 minutes (if measured)
• Nausea grade (none / mild / moderate / severe)
• Any other observed effects
• Whether sexual activity occurred and whether the adolescent reported subjective benefit

This documentation pattern mirrors the adverse event diary methodology used in FDA-mandated post-marketing surveillance studies [12]. Bringing the log to each clinical visit gives the prescribing clinician the data needed to adjust or continue therapy.

Summary of Caregiver Responsibilities by Time Point

| Time Point | Caregiver Action | |---|---| | 60 minutes before activity | Gather supplies; administer ondansetron if prescribed | | 45 minutes before activity | Administer bremelanotide injection; record pre-injection BP and HR | | 60 minutes post-injection | Re-check BP if symptomatic or per clinician instruction | | 2 to 4 hours post-injection | Assess for persistent nausea; check injection site | | 24 to 48 hours post-injection | Inspect injection site for hyperpigmentation; log observations | | Each clinical visit | Bring administration log; report any new medications |